LSZ-102 is primarily utilized in the field of oncology research, particularly in the study and treatment of hormone receptor-positive breast cancer. It functions as a selective estrogen receptor degrader (SERD), which helps in reducing the growth of cancer cells by degrading estrogen receptors and blocking estrogen signaling pathways. This makes it a promising candidate for patients who have developed resistance to traditional hormone therapies. Additionally, LSZ-102 is being investigated for its potential in combination therapies, where it may enhance the efficacy of other anticancer drugs. Its role in clinical trials continues to expand as researchers explore its broader applications in managing various types of hormone-dependent cancers.